Intellia Therapeutics (NTLA) Other Gross PP&E Adjustments: 2015-2025
Historic Other Gross PP&E Adjustments for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -$120.6 million.
- Intellia Therapeutics' Other Gross PP&E Adjustments fell 17.09% to -$120.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$538.7 million, marking a year-over-year decrease of 34.85%. This contributed to the annual value of -$145.1 million for FY2024, which is 98.28% down from last year.
- Latest data reveals that Intellia Therapeutics reported Other Gross PP&E Adjustments of -$120.6 million as of Q3 2025, which was up 8.50% from -$131.8 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Other Gross PP&E Adjustments registered a high of -$5.5 million during Q2 2021, and its lowest value of -$145.1 million during Q4 2024.
- For the 3-year period, Intellia Therapeutics' Other Gross PP&E Adjustments averaged around -$119.7 million, with its median value being -$120.6 million (2025).
- In the last 5 years, Intellia Therapeutics' Other Gross PP&E Adjustments skyrocketed by 78.28% in 2021 and then plummeted by 1,297.48% in 2022.
- Over the past 5 years, Intellia Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at -$39.8 million in 2021, then plummeted by 137.15% to -$94.5 million in 2022, then rose by 22.55% to -$73.2 million in 2023, then tumbled by 98.28% to -$145.1 million in 2024, then decreased by 17.09% to -$120.6 million in 2025.
- Its Other Gross PP&E Adjustments was -$120.6 million in Q3 2025, compared to -$131.8 million in Q2 2025 and -$141.2 million in Q1 2025.